Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome

Renato de Filippis; Pasquale De Fazio; John M Kane; Georgios Schoretsanitis

doi:10.1080/14740338.2022.2066078

Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome

Expert Opin Drug Saf. 2022 May;21(5):585-587. doi: 10.1080/14740338.2022.2066078. Epub 2022 Apr 18.

Authors

Renato de Filippis^{1

2}, Pasquale De Fazio¹, John M Kane^{3

4

5}, Georgios Schoretsanitis^{2

3

4}

Affiliations

¹ Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
² Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland.
³ The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA.
⁴ Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY, USA.
⁵ Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA.

PMID: 35417282
DOI: 10.1080/14740338.2022.2066078

No abstract available

Keywords: Antipsychotic agents; clozapine; drug hypersensitivity syndrome; drug-related side-effects and adverse reactions; neglected diseases; orphan drug production; pharmacoepidemiology; pharmacovigilance; schizophrenia; undiagnosed diseases.

Publication types

Editorial

MeSH terms

Clozapine* / adverse effects
Drug Hypersensitivity Syndrome* / diagnosis
Drug Hypersensitivity Syndrome* / etiology
Humans
Pharmacovigilance

Substances

Clozapine